pharmacogenetic guidelines for 5 amino 1mq 5-Amino-1MQ Research Compound Peptide Therapy - 5-Amino-1MQ –

Category 1 status simply indicates the substance may be compounded under interim policy it does not establish proven safety, efficacy, or standardized dosing

For more information, call us today or book an appointment online

The key to minimizing aod 9604 peptide side effects lies in proper screening, graduated dosing approaches, quality sourcing, and comprehensive monitoring protocols

AOD 9604 doesn't affect IGF-1 levels, so there's no concern about unwanted tissue growth or increased cancer risk

Any administration to humans or animals, whether by ingestion, injection, or other means, is strictly prohibited by law